October 30, 2015 by Dan • Commentary

This morning, hedge fund heavyweight and founder of Pershing Square Bill Ackman is holding a call with investors and the financial press to answer questions about his nearly $2 billion stake in specialty pharmaceuticals company Valeant …

Continue reading
October 27, 2015 by Dan • Commentary

This Valeant (VRX) story is far from done.  For those that thought the volatility in the stock was brought on solely by some shadowy short biased research house, think again. The  WSJ set its sites on …

Continue reading
November 12, 2014 by Dan • Commentary

Last week following QCOM’s disappointing fiscal Q4 results we laid out our thoughts (below), and offered a longer term bullish outlook for the shares once a few minor issues like probes from regulators and issues …

Continue reading